For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

KAMPALA - Dr Matthias Magoola says the US Patent and Trademark Office (USPTO) has granted a patent for his invention of the first treatment of cancer using a novel composition of a guided Ribonucleic ...

The EU CRISPR patent landscape: a complex battle In the patent field, CRISPR/Cas technology has sparked intense patent battles in Europe, with significant implications for innovation and market ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

It would also essentially consolidate most of the CRISPR/Cas9 patents, hopefully curbing future litigation and saving royalties. The market cap of Editas, however, would indicate that the value of ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

Broad Institute regarding invention of the groundbreaking CRISPR-Cas9 gene-editing technology ... and the threat of enforcement surrounding alleged improper patent listings, and was capped ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

ERS Genomics Limited has announced a new license agreement with Cytosurge AG. This is a non-exclusive licensing agreement granting Cytosurge access to the ERS CRISPR/Cas9 patent portfolio. Never miss ...

An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license. DUBLIN and CHESHIRE, United Kingdom ...